CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple ...
Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (AU-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma ...
BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences (AURA), Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve ...
BOSTON--(BUSINESS WIRE)-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology ...
BOSTON--(BUSINESS WIRE)-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology ...
Credit: Axsome Therapeutics Symbravo is expected to be available in approximately 4 months. Symbravo is not substitutable with other formulations of meloxicam or rizatriptan. The Food and Drug ...
Aura's stock jumps 11% after announcing Fast Track status for its bladder cancer treatment candidate
Shares of Aura Biosciencs Inc. were up 11.3% in premarket trading on Thursday after the company said it received a Fast-Track designation from the Food and Drug Administration for its experimental ...
9don MSN
Combined oral contraceptive use among people with migraine with aura persists despite cautions
Current medical guidelines discourage the use of combined oral contraceptives (COCs) among people who experience migraine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback